<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344769</url>
  </required_header>
  <id_info>
    <org_study_id>17-008806</org_study_id>
    <secondary_id>R21DK118391</secondary_id>
    <nct_id>NCT04344769</nct_id>
  </id_info>
  <brief_title>Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)</brief_title>
  <official_title>Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant&#xD;
      response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while&#xD;
      identifying candidate biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracellular Reactive Oxygen Species (ROS) concentration is a major determinant of cellular&#xD;
      fate and is finely regulated by the cell's antioxidant systems. While low levels of ROS are&#xD;
      required for pro-survival signaling, cell proliferation, growth, and energy metabolism, the&#xD;
      excess of ROS or oxidative stress leads to inflammation, cell death, and disease/injury&#xD;
      progression. Indeed, oxidative stress is commonly observed in several renal diseases&#xD;
      including ADPKD. On the other hand, a surplus of antioxidants will not only neutralize ROS,&#xD;
      but may result in the antithesis of oxidative stress, which is known as reductive stress. The&#xD;
      Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor that integrates&#xD;
      cellular stress signals and responds by regulating the expression of several antioxidant&#xD;
      proteins. Activation of the Nrf2-mediated antioxidant defense pathway enhances ROS&#xD;
      detoxification, conferring a more reduced intracellular environment that can promote cell&#xD;
      survival and proliferation, a distinctive feature in ADPKD that underlies cyst formation and&#xD;
      enlargement. Therefore, a better characterization of ROS levels and antioxidant response in&#xD;
      ADPKD patients would allow development of more specific and effective therapies, while&#xD;
      providing additional related biomarkers.&#xD;
&#xD;
      The investigators broad objective is to characterize oxidative stress and the Nrf2&#xD;
      antioxidant response in early stages of ADPKD, while identifying candidate biomarkers.&#xD;
&#xD;
      Participants in this study will have a blood and a urine sample collected to determine&#xD;
      biomarkers of oxidative status and antioxidant response to study redox balance at early&#xD;
      stages of the disease. In addition, an abdominal MRI will be performed to determine patient's&#xD;
      total kidney volume (TKV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Oxidative Status</measure>
    <time_frame>Baseline</time_frame>
    <description>Determination of common biomarkers of oxidative damage including but not limited to: 8-oxodeoxyguanosine, F2-isoprostanes, from urine and plasma samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Antioxidant Response</measure>
    <time_frame>Baseline</time_frame>
    <description>Determination of antioxidants including but not limited to: Heme Oxygenase 1 (HO-1), Superoxide dismutase (SOD), catalase, glutathione reductase (GSR), glutathione peroxidase (GPx), and NAD(P)H dehydrogenase [quinone] 1 (NOQ1), glutathione, Nrf2 from urine and plasma samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total kidney volume (TKV)</measure>
    <time_frame>Baseline</time_frame>
    <description>Determined by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Kidney Injury</measure>
    <time_frame>Baseline</time_frame>
    <description>Determination of kidney injury biomarkers including but not limited to: Kidney Injury Molecule 1 (KIM-1), Neutrophil gelatinase-associated lipocalin (NGAL), Monocyte chemotactic protein-1 (MCP-1), Transforming growth factor-β1 (TGF-β1),</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Patients with a previous diagnosis of ADPKD</arm_group_label>
    <description>Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy individuals as controls</arm_group_label>
    <description>Age and gender-matched healthy controls</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine and plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients with a previous diagnosis of ADPKD that meet the inclusion&#xD;
        criteria. In addition, patients will be matched 1:1 to age and gender healthy volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (ADPKD Subjects):&#xD;
&#xD;
          -  ADPKD (based on Ravine et al. criteria)&#xD;
&#xD;
          -  Class 1 B-E according to our imaging classification&#xD;
&#xD;
          -  Male and female subjects 18 - 30 years of age, inclusive&#xD;
&#xD;
          -  Estimated GFR&gt; 60 mL/min/m2 (CKD-EPI equation)&#xD;
&#xD;
          -  Ability to provide written, informed consent.&#xD;
&#xD;
        Exclusion Criteria (ADPKD Subjects):&#xD;
&#xD;
          -  Class 2 according to our imaging classification&#xD;
&#xD;
          -  Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)&#xD;
&#xD;
          -  Diabetes mellitus (fasting glucose &gt; 126 mg/dL or treatment with insulin or oral&#xD;
             hypoglycemics).&#xD;
&#xD;
          -  Predicted urine protein excretion in urinalysis &gt;1 g/24 hrs&#xD;
&#xD;
          -  Abnormal urinalysis suggestive of concomitant glomerular disease.&#xD;
&#xD;
          -  Subjects having contraindications to, or interference with MRI assessments. [For&#xD;
             example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large&#xD;
             abdominal/back tattoos, etc].&#xD;
&#xD;
          -  Female subjects that are pregnant&#xD;
&#xD;
        Inclusion Criteria (Healthy Subjects):&#xD;
&#xD;
          -  Male and female subjects 18 - 30 years of age, inclusive&#xD;
&#xD;
          -  Estimated GFR&gt; 60 mL/min/m2 (CKD-EPI equation)&#xD;
&#xD;
          -  Ability to provide written, informed consent.&#xD;
&#xD;
        Exclusion Criteria (Healthy Subjects):&#xD;
&#xD;
          -  Previous personal or family history of kidney disease.&#xD;
&#xD;
          -  Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)&#xD;
&#xD;
          -  Diabetes mellitus (fasting glucose &gt; 126 mg/dL or treatment with insulin or oral&#xD;
             hypoglycemics).&#xD;
&#xD;
          -  Presence of proteinuria&#xD;
&#xD;
          -  Abnormal urinalysis suggestive glomerular disease.&#xD;
&#xD;
          -  Subjects having contraindications to, or interference with MRI assessments. [For&#xD;
             example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large&#xD;
             abdominal/back tattoos, etc]&#xD;
&#xD;
          -  Female subjects that are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria V. Irazabal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Translational PKD Center, Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Leistikow</last_name>
    <phone>(507) 266-1316</phone>
    <email>leistikow.kathleen@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Madsen</last_name>
    <phone>507-266-9391</phone>
    <email>madsen.charles@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Maria V. Irazabal Mira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Oxidative Stress</keyword>
  <keyword>Antioxidant Response</keyword>
  <keyword>Nrf2</keyword>
  <keyword>ADPKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

